Bayer AG (BAY.F) Says Blood Thinner Cuts Risk of Repeat Heart Attack
8/29/2012 7:36:46 AM
Bayer said results from a late-stage clinical trial showed its anti-clotting pill Xarelto cut the risk of recurrence in patients who have suffered a severe heart attack, as it strives to secure U.S. approval for wider use of the drug. Results from the trial showed that adding Xarelto to standard therapy - typically aspirin and Sanofi's Plavix - significantly reduced cardiovascular death, heart attack or stroke compared with standard therapy alone. The results came from the analysis of a sub-group of patients in a wider drug trial that tested the blood clot preventer on patients with acute coronary syndrome (ACS).